Reviews Synercid


No reviews yet.

Synercid Drug Description
Synercid® I.V.
(quinupristin and dalfopristin) for Injection

One of Synercid's approved indications is for the treatment of patients
with serious or life-threatening infections associated with vancomycin-resistant
Enterococcus faecium (VREF) bacteremia. Synercid has been approved
for marketing in the United States for this indication under FDA's of products
for use in life-threatening conditions when other therapies are not available.
Approval of drugs for marketing under these regulations is based upon a demonstrated
effect on a surrogate endpoint that is likely to predict clinical benefit.
Approval of this indication is based upon Synercid's ability to clear
VREF from the bloodstream, with clearance of bacteremia considered to be a surrogate
endpoint. There are no results from well-controlled clinical studies that confirm
the validity of this surrogate marker. However, a study to verify the clinical
benefit of therapy with Synercid on traditional clinical endpoints (such
as cure of the underlying infection) is presently underway.

DRUG DESCRIPTION



What are the possible side effects of dalfopristin and quinupristin (Synercid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

diarrhea that is watery or bloody;
jaundice (yellowing of the skin or eyes);
fever, sore throat, and headache with a severe blistering, peeling, and red skin rash;
confusion, seizure (convulsions);
...
Read All Potential Side Effects for Synercid »




Synercid® (quinupristin and dalfopristin powder for injection) I.V., a
streptogramin antibacterial agent for intravenous administration, is a sterile
lyophilized formulation of two semisynthetic pristinamycin derivatives, quinupristin
(derived from pristinamycin I) and dalfopristin (derived from pristinamycin
IIA) in the ratio of 30:70 (w/w).
Quinupristin is a white to very slightly yellow, hygroscopic powder. It is
a combination of three peptide macrolactones. The main component of quinupristin
( > 88.0%) has the following chemical name: N­ [(6R,9S,10R,13S,15aS,18R,22S,24aS)-22-[p-(dimethylamino)benzyl]-6-ethyldocosahydro-10,23-dimethyl­5,8,12,15,17,21,24-heptaoxo-13-phenyl-18-[[(3S)-3-quinuclidinylthio]
methyl]-12H-pyrido[2,1-]pyrrolo-[2,1­ f l][1,4,7,10,13,16] oxapentaazacyclononadecin-9-yl]-3-hydroxypicolinamide.

The main component of quinupristin has an empirical formula of C53H67N9O10S,
a molecular weight of 1022.24 and the following structural formula:








Dalfopristin is a slightly yellow to yellow, hygroscopic, powder. The chemical
name for dalfopristin is: (3R,4R,5E,10E,12E,14S,26R,26aS)-26-[[2-(diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14­hydroxy-3-isopropyl-4,12-dimethyl-3H-21,18-nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]-dioxadiazacyclotetracosine­1,7,16,22(4H,17H)-tetrone.

Dalfopristin has an empirical formula of C34H50N4O9S,
a molecular weight of 690.85 and the following structural formula:







Last reviewed on RxList: 7/9/2008




Synercid Drug Description
Synercid® I.V.
(quinupristin and dalfopristin) for Injection

One of Synercid's approved indications is for the treatment of patients
with serious or life-threatening infections associated with vancomycin-resistant
Enterococcus faecium (VREF) bacteremia. Synercid has been approved
for marketing in the United States for this indication under FDA's of products
for use in life-threatening conditions when other therapies are not available.
Approval of drugs for marketing under these regulations is based upon a demonstrated
effect on a surrogate endpoint that is likely to predict clinical benefit.
Approval of this indication is based upon Synercid's ability to clear
VREF from the bloodstream, with clearance of bacteremia considered to be a surrogate
endpoint. There are no results from well-controlled clinical studies that confirm
the validity of this surrogate marker. However, a study to verify the clinical
benefit of therapy with Synercid on traditional clinical endpoints (such
as cure of the underlying infection) is presently underway.

DRUG DESCRIPTION



What are the possible side effects of dalfopristin and quinupristin (Synercid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

diarrhea that is watery or bloody;
jaundice (yellowing of the skin or eyes);
fever, sore throat, and headache with a severe blistering, peeling, and red skin rash;
confusion, seizure (convulsions);
...
Read All Potential Side Effects for Synercid »




Synercid® (quinupristin and dalfopristin powder for injection) I.V., a
streptogramin antibacterial agent for intravenous administration, is a sterile
lyophilized formulation of two semisynthetic pristinamycin derivatives, quinupristin
(derived from pristinamycin I) and dalfopristin (derived from pristinamycin
IIA) in the ratio of 30:70 (w/w).
Quinupristin is a white to very slightly yellow, hygroscopic powder. It is
a combination of three peptide macrolactones. The main component of quinupristin
( > 88.0%) has the following chemical name: N­ [(6R,9S,10R,13S,15aS,18R,22S,24aS)-22-[p-(dimethylamino)benzyl]-6-ethyldocosahydro-10,23-dimethyl­5,8,12,15,17,21,24-heptaoxo-13-phenyl-18-[[(3S)-3-quinuclidinylthio]
methyl]-12H-pyrido[2,1-]pyrrolo-[2,1­ f l][1,4,7,10,13,16] oxapentaazacyclononadecin-9-yl]-3-hydroxypicolinamide.

The main component of quinupristin has an empirical formula of C53H67N9O10S,
a molecular weight of 1022.24 and the following structural formula:








Dalfopristin is a slightly yellow to yellow, hygroscopic, powder. The chemical
name for dalfopristin is: (3R,4R,5E,10E,12E,14S,26R,26aS)-26-[[2-(diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14­hydroxy-3-isopropyl-4,12-dimethyl-3H-21,18-nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]-dioxadiazacyclotetracosine­1,7,16,22(4H,17H)-tetrone.

Dalfopristin has an empirical formula of C34H50N4O9S,
a molecular weight of 690.85 and the following structural formula:







Last reviewed on RxList: 7/9/2008




Synercid Drug Description
Synercid® I.V.
(quinupristin and dalfopristin) for Injection

One of Synercid's approved indications is for the treatment of patients
with serious or life-threatening infections associated with vancomycin-resistant
Enterococcus faecium (VREF) bacteremia. Synercid has been approved
for marketing in the United States for this indication under FDA's of products
for use in life-threatening conditions when other therapies are not available.
Approval of drugs for marketing under these regulations is based upon a demonstrated
effect on a surrogate endpoint that is likely to predict clinical benefit.
Approval of this indication is based upon Synercid's ability to clear
VREF from the bloodstream, with clearance of bacteremia considered to be a surrogate
endpoint. There are no results from well-controlled clinical studies that confirm
the validity of this surrogate marker. However, a study to verify the clinical
benefit of therapy with Synercid on traditional clinical endpoints (such
as cure of the underlying infection) is presently underway.

DRUG DESCRIPTION



What are the possible side effects of dalfopristin and quinupristin (Synercid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

diarrhea that is watery or bloody;
jaundice (yellowing of the skin or eyes);
fever, sore throat, and headache with a severe blistering, peeling, and red skin rash;
confusion, seizure (convulsions);
...
Read All Potential Side Effects for Synercid »




Synercid® (quinupristin and dalfopristin powder for injection) I.V., a
streptogramin antibacterial agent for intravenous administration, is a sterile
lyophilized formulation of two semisynthetic pristinamycin derivatives, quinupristin
(derived from pristinamycin I) and dalfopristin (derived from pristinamycin
IIA) in the ratio of 30:70 (w/w).
Quinupristin is a white to very slightly yellow, hygroscopic powder. It is
a combination of three peptide macrolactones. The main component of quinupristin
( > 88.0%) has the following chemical name: N­ [(6R,9S,10R,13S,15aS,18R,22S,24aS)-22-[p-(dimethylamino)benzyl]-6-ethyldocosahydro-10,23-dimethyl­5,8,12,15,17,21,24-heptaoxo-13-phenyl-18-[[(3S)-3-quinuclidinylthio]
methyl]-12H-pyrido[2,1-]pyrrolo-[2,1­ f l][1,4,7,10,13,16] oxapentaazacyclononadecin-9-yl]-3-hydroxypicolinamide.

The main component of quinupristin has an empirical formula of C53H67N9O10S,
a molecular weight of 1022.24 and the following structural formula:








Dalfopristin is a slightly yellow to yellow, hygroscopic, powder. The chemical
name for dalfopristin is: (3R,4R,5E,10E,12E,14S,26R,26aS)-26-[[2-(diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14­hydroxy-3-isopropyl-4,12-dimethyl-3H-21,18-nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]-dioxadiazacyclotetracosine­1,7,16,22(4H,17H)-tetrone.

Dalfopristin has an empirical formula of C34H50N4O9S,
a molecular weight of 690.85 and the following structural formula:







Last reviewed on RxList: 7/9/2008




Synercid Drug Description
Synercid® I.V.
(quinupristin and dalfopristin) for Injection

One of Synercid's approved indications is for the treatment of patients
with serious or life-threatening infections associated with vancomycin-resistant
Enterococcus faecium (VREF) bacteremia. Synercid has been approved
for marketing in the United States for this indication under FDA's of products
for use in life-threatening conditions when other therapies are not available.
Approval of drugs for marketing under these regulations is based upon a demonstrated
effect on a surrogate endpoint that is likely to predict clinical benefit.
Approval of this indication is based upon Synercid's ability to clear
VREF from the bloodstream, with clearance of bacteremia considered to be a surrogate
endpoint. There are no results from well-controlled clinical studies that confirm
the validity of this surrogate marker. However, a study to verify the clinical
benefit of therapy with Synercid on traditional clinical endpoints (such
as cure of the underlying infection) is presently underway.

DRUG DESCRIPTION



What are the possible side effects of dalfopristin and quinupristin (Synercid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

diarrhea that is watery or bloody;
jaundice (yellowing of the skin or eyes);
fever, sore throat, and headache with a severe blistering, peeling, and red skin rash;
confusion, seizure (convulsions);
...
Read All Potential Side Effects for Synercid »




Synercid® (quinupristin and dalfopristin powder for injection) I.V., a
streptogramin antibacterial agent for intravenous administration, is a sterile
lyophilized formulation of two semisynthetic pristinamycin derivatives, quinupristin
(derived from pristinamycin I) and dalfopristin (derived from pristinamycin
IIA) in the ratio of 30:70 (w/w).
Quinupristin is a white to very slightly yellow, hygroscopic powder. It is
a combination of three peptide macrolactones. The main component of quinupristin
( > 88.0%) has the following chemical name: N­ [(6R,9S,10R,13S,15aS,18R,22S,24aS)-22-[p-(dimethylamino)benzyl]-6-ethyldocosahydro-10,23-dimethyl­5,8,12,15,17,21,24-heptaoxo-13-phenyl-18-[[(3S)-3-quinuclidinylthio]
methyl]-12H-pyrido[2,1-]pyrrolo-[2,1­ f l][1,4,7,10,13,16] oxapentaazacyclononadecin-9-yl]-3-hydroxypicolinamide.

The main component of quinupristin has an empirical formula of C53H67N9O10S,
a molecular weight of 1022.24 and the following structural formula:








Dalfopristin is a slightly yellow to yellow, hygroscopic, powder. The chemical
name for dalfopristin is: (3R,4R,5E,10E,12E,14S,26R,26aS)-26-[[2-(diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14­hydroxy-3-isopropyl-4,12-dimethyl-3H-21,18-nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]-dioxadiazacyclotetracosine­1,7,16,22(4H,17H)-tetrone.

Dalfopristin has an empirical formula of C34H50N4O9S,
a molecular weight of 690.85 and the following structural formula:







Last reviewed on RxList: 7/9/2008




Synercid Drug Description
Synercid® I.V.
(quinupristin and dalfopristin) for Injection

One of Synercid's approved indications is for the treatment of patients
with serious or life-threatening infections associated with vancomycin-resistant
Enterococcus faecium (VREF) bacteremia. Synercid has been approved
for marketing in the United States for this indication under FDA's of products
for use in life-threatening conditions when other therapies are not available.
Approval of drugs for marketing under these regulations is based upon a demonstrated
effect on a surrogate endpoint that is likely to predict clinical benefit.
Approval of this indication is based upon Synercid's ability to clear
VREF from the bloodstream, with clearance of bacteremia considered to be a surrogate
endpoint. There are no results from well-controlled clinical studies that confirm
the validity of this surrogate marker. However, a study to verify the clinical
benefit of therapy with Synercid on traditional clinical endpoints (such
as cure of the underlying infection) is presently underway.

DRUG DESCRIPTION



What are the possible side effects of dalfopristin and quinupristin (Synercid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

diarrhea that is watery or bloody;
jaundice (yellowing of the skin or eyes);
fever, sore throat, and headache with a severe blistering, peeling, and red skin rash;
confusion, seizure (convulsions);
...
Read All Potential Side Effects for Synercid »




Synercid® (quinupristin and dalfopristin powder for injection) I.V., a
streptogramin antibacterial agent for intravenous administration, is a sterile
lyophilized formulation of two semisynthetic pristinamycin derivatives, quinupristin
(derived from pristinamycin I) and dalfopristin (derived from pristinamycin
IIA) in the ratio of 30:70 (w/w).
Quinupristin is a white to very slightly yellow, hygroscopic powder. It is
a combination of three peptide macrolactones. The main component of quinupristin
( > 88.0%) has the following chemical name: N­ [(6R,9S,10R,13S,15aS,18R,22S,24aS)-22-[p-(dimethylamino)benzyl]-6-ethyldocosahydro-10,23-dimethyl­5,8,12,15,17,21,24-heptaoxo-13-phenyl-18-[[(3S)-3-quinuclidinylthio]
methyl]-12H-pyrido[2,1-]pyrrolo-[2,1­ f l][1,4,7,10,13,16] oxapentaazacyclononadecin-9-yl]-3-hydroxypicolinamide.

The main component of quinupristin has an empirical formula of C53H67N9O10S,
a molecular weight of 1022.24 and the following structural formula:








Dalfopristin is a slightly yellow to yellow, hygroscopic, powder. The chemical
name for dalfopristin is: (3R,4R,5E,10E,12E,14S,26R,26aS)-26-[[2-(diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14­hydroxy-3-isopropyl-4,12-dimethyl-3H-21,18-nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]-dioxadiazacyclotetracosine­1,7,16,22(4H,17H)-tetrone.

Dalfopristin has an empirical formula of C34H50N4O9S,
a molecular weight of 690.85 and the following structural formula:







Last reviewed on RxList: 7/9/2008





Other reviews about Synercid on wordpress

Antibiotic Gumbo
  by Apollo
In my bwain “There’s a little chef… in your bwain?” - Colette, Ratatouille We’re half-way through Medical Microbiology and finished with most medically-important bacterial and fungal species; within another few […]


Antibiotic-Resistant Disease Killing Humans and Swine
  by Boulderdash
Did you realize that 70% of All Antibiotic Use Is In Agriculture ? Source: Dr Mercola The antibiotic-resistant bacteria Extended Spectrum Beta Lactamase (ESBL) is killing both people and […]


Schering's Levitra, Others, May Lead to Dangerous Side Effects if Combined With Any of 56 Common Medicines, Consumer Advocates Say. . . .
  by condor
Bloomberg is pushing a story, tonight, that highlights the serious side-effect risks associated with the entire currently-approved class of so-called "erectile dysfunction" drugs: they shouldn't be taken with […]


The Quinolones
  by bloghealthblog
Cialis super active new medication at our canadian pharmacy shop. Although there have been some new antibiotics over the last few years, the vast majority of the […]


Antibiotic-Resistant Disease Affecting People and Swine
  by Dallas Cove
The antibiotic-resistant bacteria Extended Spectrum Beta Lactamase (ESBL) is killing both people and swine in Denmark. The bacteria has been implicated in the deaths of a number of cancer […]


Linezolid
  by mickynolt1985
Linezolid (INN) (pronounced /lɪˈnɛzəlÉŞd/, li-NE-zə-lid) is a synthetic antibiotic used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics. A […]


Notes on bacteriophages
  by writery
From wikipedia:BacteriophageA bacteriophage (from 'bacteria' and Greek φᾰγεῖν phagein "to eat") is any one of a number of viruses that infect bacteria. Bacteriophages are among the most common […]


MRSA Comings and Goings: Sid Harth
  by navanavonmilita
[caption id="attachment_4464" align="aligncenter" width="320" caption="MRSA-Enlarged"][/caption] [caption id="attachment_4463" align="aligncenter" width="175" caption="MRSA-Bacteria"][/caption] MRSA Comings and Goings: Sid Harth Google Translate India trashes 'superbug' report, says it's doctored Pushpa Narayan, TNN, Aug 13, 2010, 12.24am IST Comments […]


MRSA - Superbugs in our food?
  by givingglory
Maryn McKenna may be the premier U.S. public health journalist. Her nickname is "Scary Disease Girl," which she acquired filing reports from places such as a graveyard within […]



Other reviews about Synercid on web:

Learn about the prescription medication Synercid (Quinupristin and Dalfopristin), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Synercid (Quinupristin and Dalfopristin) Drug Information: Uses ...


Accurate, FDA approved Synercid information for healthcare professionals and patients - brought to you by Drugs.com. Synercid Official FDA information, side effects and uses.


Quinupristin/dalfopristin (trade name Synercid) is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. Quinupristin/dalfopristin - Wikipedia, the free encyclopedia


All about Synercid. View complete and up to date Synercid information - part of the Drugs.com trusted medication database. Synercid Facts and Comparisons at Drugs.com


King Pharmaceuticals, established in 1994, is a vertically integrated branded pharmaceutical company that performs basic research and develops, manufactures, markets and sells ... King Pharmaceuticals®, Inc. - A Vertically Integrated Branded ...


Find patient medical information for Synercid IV on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Synercid IV : Uses, Side Effects, Interactions, Pictures, Warnings ...


Drug information and side-effects for Synercid I.V. ... Useful Websites. Medical Tourism Compare and save on surgery Global Translations Synercid I.V. - Drug information from MediLexicon


What is Synercid (Dalfopristin Quinupristin)? Dalfopristin and quinupristin is a combination antibiotic that fights severe or life-threatening infection caused by bacteria. Synercid - Drugs & Treatments - Revolution Health


Synercid (150mg of quinupristin and 350mg of dalfopristin) - Intravenous (IV) Dilution Synercid (150mg of quinupristin and 350mg of dalfopristin ...


Consumer information and patient comments on perscription drugs ... We currently have info on 350 drugs Users have posted 4369 comments Synercid - The Internet Drug Database





Featured Reviews

Reviews Nexium

Nexium Drug Description NEXIUM (esomeprazole magnesium) Delayed-Release Capsules NEXIUM (esomeprazole magnesium) For Delayed-Release Oral Suspension DRUG DESCRIPTION What are the possible side effects of esomeprazole (Nexium)? Get...
Read More  |  Review This
Reviews Dimetane

Dimetane Drug Description Dimetane (brompheniramine, phenylpropanolamine, codeine) DRUG DESCRIPTION What are the possible side effects of brompheniramine? Stop taking brompheniramine and seek emergency medical attention if...
Read More  |  Review This
Reviews Dextroamphetamine

Dexedrine Drug Description DEXEDRINE® (dextroamphetamine sulfate) SPANSULE® Sustained-Release Capsules WARNING AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME...
Read More  |  Review This
Reviews Lepirudin

Refludan Drug Description REFLUDAN ® 50 mg/Vial [lepirudin (rDNA)] For Injection DRUG DESCRIPTION What are the possible side effects of lepirudin (Refludan)? Get emergency medical help if you have any of these signs of an...
Read More  |  Review This
Reviews Multihance

Multihance Drug Description MultiHance (gadobenate dimeglumine) Injection WARNING: NEPHROGENIC SYSTEMIC FIBROSIS NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF)...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....